Is Achaogen Inc (NASDAQ:AKAO) a Buy? The Stock Reported more Sellers

April 17, 2018 - By reb123z

Achaogen, Inc. (NASDAQ:AKAO) Logo

Investors sentiment increased to 1.32 in Q4 2017. Its up 0.16, from 1.16 in 2017Q3. It improved, as 16 investors sold Achaogen, Inc. shares while 21 reduced holdings. 22 funds opened positions while 27 raised stakes. 29.75 million shares or 6.36% less from 31.77 million shares in 2017Q3 were reported.
Polar Limited Liability Partnership reported 1.88M shares. 53,853 were reported by California State Teachers Retirement Systems. Voya Inv Management Llc stated it has 15,435 shares or 0% of all its holdings. Wells Fargo And Com Mn accumulated 0% or 50,683 shares. 7,287 are owned by Bnp Paribas Arbitrage. Group One Trading L P invested in 0.01% or 94,980 shares. Us Bankshares De accumulated 6,119 shares. Winch Advisory Ser Lc stated it has 0% in Achaogen, Inc. (NASDAQ:AKAO). 28,629 were accumulated by Iconiq Ltd Com. Bankshares Of Mellon owns 144,843 shares for 0% of their portfolio. Royal Bancshares Of Canada invested in 0% or 677 shares. Citigroup Incorporated invested in 92,949 shares or 0% of the stock. The California-based Parallax Volatility Advisers Limited Partnership has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Ameritas Investment Ptnrs invested 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO). Vanguard Group invested 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO).

Since December 18, 2017, it had 9 insider purchases, and 5 selling transactions for $10.50 million activity. On Monday, April 2 DUGGAN ROBERT W bought $1.14 million worth of Achaogen, Inc. (NASDAQ:AKAO) or 91,461 shares. $49,146 worth of stock was sold by Hillan Kenneth J. on Wednesday, February 21. Schilke Tobin sold $11,822 worth of stock. Another trade for 1,640 shares valued at $17,499 was made by Wise Blake on Wednesday, February 21.

The stock of Achaogen Inc (NASDAQ:AKAO) registered an increase of 4.43% in short interest. AKAO’s total short interest was 11.52 million shares in April as published by FINRA. Its up 4.43% from 11.03 million shares, reported previously. With 1.55M shares average volume, it will take short sellers 7 days to cover their AKAO’s short positions. The short interest to Achaogen Inc’s float is 37.02%.

The stock increased 1.31% or $0.16 during the last trading session, reaching $12.37. About 530,979 shares traded. Achaogen, Inc. (NASDAQ:AKAO) has declined 41.74% since April 17, 2017 and is downtrending. It has underperformed by 53.29% the S&P500.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $553.25 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Coverage

Among 6 analysts covering Achaogen (NASDAQ:AKAO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Achaogen had 7 analyst reports since October 24, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 28 by Mizuho. The firm earned “Buy” rating on Wednesday, February 14 by Wedbush. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, February 28. The firm earned “Buy” rating on Wednesday, February 28 by Needham. Stifel Nicolaus maintained it with “Buy” rating and $27.0 target in Thursday, November 9 report. The firm has “Buy” rating given on Tuesday, January 2 by Cowen & Co.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: